Cyclopharm unveils groundbreaking study results

Cyclopharm (ASX:CYC) has announced the publication of its first US-based clinical study demonstrating the effectiveness of its Technegas technology for lung transplant evaluations. Conducted by clinicians at Washington University's Mallinckrodt Institute of Radiology, the study highlights Technegas' superior clinical efficacy compared to the current US standard, 133-Xenon.

Cyclopharm's strategic outlook on US market expansion

Cyclopharm is positioning its Technegas technology as a key tool in the US healthcare market following the publication of a clinical study showcasing its efficacy in lung transplant evaluations. The study, conducted on 74 patients, demonstrated Technegas' superior performance over the current standard, 133-Xenon, particularly in obstructive lung disease cases. With FDA approval and reimbursement, Cyclopharm aims to expand its market share in the US, a market valued at over USD $1 billion. Technegas, already proven in 66 countries, offers cost-efficiency and is compatible with advanced imaging techniques. The company is focused on broadening its applications to conditions beyond pulmonary embolism, enhancing patient care and clinical outcomes.

Executive insights on Technegas study

The publication of this study is a significant milestone for Cyclopharm as it validates the clinical advantages of Technegas over existing radiopharmaceuticals in the US market. This positions us well to not only replace the current standard but also challenge alternative imaging modalities with higher radiation, such as CTPA.